CFDA Issued Four Registration Guidelines

December 22 2017, China Food and Drug Administration (CFDA) issued four new registration guideline.

Registration guideline

Scope of application

Automatic blood type analyzer Registration guideline.


This guideline can apply to automatic blood type analyzer that conduct Blood group identification, antibody screening, cross-matching and etc. for the human blood type through test tube method, microporous plate method or column agglutination method.

ABO、RhD blood type antigen detection card(Column agglutination method) Registration guideline


This guideline can apply to ABO、RhD blood type antigen detection card(Column agglutination method) and column agglutination method blood type detection card including ABO、RhD blood type antigen detection usage.

Human Epidermal Growth Factor receptor 2 gene amplification test kit (fluorescence in situ hybridization) Registration guideline.


This guideline can apply to the fluorescence in situ hybridization method used to detect HER2 gene amplification in the biopsy samples and biopsy samples. It includes HER2 gene average copy number (single signal),HER2 gene average copy number and the ratio of the average copy number of chromosome 17 (CEP17) in chromosome 17 of the gene (double signal).

Hepatitis c viral nucleic acid genotyping test kit Registration guideline


This guideline can apply to HCV nucleic acid genotyping test kit that based on PCR(polymerase chain reaction)method. 

* If you have any comments or questions, please contact us at

Contact Us
CIRS China

Ms. Shuo Wang (Head office)
Tel: +86-571 8720 6559 | Fax: +86-571 87206533
Mr. Edwin Wen (Beijing office)
Tel: +86-10 63984062 | Fax: +86-10 63984032

CIRS Europe

Bryan Zhou
Tel:  +353 (1)477 3710


CIRS Korea
Mr. Junho Lee 
Tel: +82 2 6347 8801